Terms: = Liver cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH
308 results:
1. Identification of drug responsible glycogene signature in liver carcinoma from meta-analysis using RNA-seq data.
Koreeda T; Honda H
Glycoconj J; 2024 Apr; 41(2):133-149. PubMed ID: 38656600
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer.
Yang H; Cheng J; Zhuang H; Xu H; Wang Y; Zhang T; Yang Y; Qian H; Lu Y; Han F; Cao L; Yang N; Liu R; Yang X; Zhang J; Wu J; Zhang N
Cancer Cell; 2024 Apr; 42(4):535-551.e8. PubMed ID: 38593780
[TBL] [Abstract] [Full Text] [Related]
3. LC-MS/MS method for the quantification of cortisol of hepatocellular carcinoma.
Zhou Z; Li X; Yin S; Zhang Z; Li X; Miao X; Cheng H; Lou Y; Tu P; Lu Y; Zhang G
Biomed Chromatogr; 2024 Apr; 38(4):e5829. PubMed ID: 38351664
[TBL] [Abstract] [Full Text] [Related]
4. Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.
Feng Y; Guo K; Jin H; Jiang J; Wang M; Lin S
Front Immunol; 2023; 14():1269067. PubMed ID: 38250059
[TBL] [Abstract] [Full Text] [Related]
5. Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
Flecchia C; Auclin E; Alouani E; Mercier M; Hollebecque A; Turpin A; Mazard T; Pernot S; Dutherage M; Cohen R; Borg C; Hautefeuille V; Sclafani F; Ben-Abdelghani M; Aparicio T; De La Fouchardière C; Herve C; Perkins G; Heinrich K; Kunzmann V; Gallois C; Guimbaud R; Tougeron D; Taieb J
Br J Cancer; 2024 Feb; 130(3):442-449. PubMed ID: 38102227
[TBL] [Abstract] [Full Text] [Related]
6. liver Mass as First-Time Diagnosis of Sarcomatoid Anaplastic Thyroid Carcinoma: A Rare Malignancy Presenting at an Unexpected Body Site.
Kamashki A; Rivera M; Sturgis CD
Am J Case Rep; 2023 Dec; 24():e941838. PubMed ID: 38041397
[TBL] [Abstract] [Full Text] [Related]
7. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Masi G; Kwiatkowski M; Lim HY; Kim JH; Breder V; Kumada H; Cheng AL; Galle PR; Kaneko S; Wang A; Mody K; Dutcus C; Dubrovsky L; Siegel AB; Finn RS;
Lancet Oncol; 2023 Dec; 24(12):1399-1410. PubMed ID: 38039993
[TBL] [Abstract] [Full Text] [Related]
8. Tissue Circular RNA_0004018 and 0003570 as Novel Prognostic Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma.
Kang MK; Kim G; Park JG; Jang SY; Lee HW; Tak WY; Kweon YO; Park SY; Lee YR; Hur K
Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895312
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological features and differential diagnosis of gastric metastases.
Chen W; Liu C; Liu Y; Yuan J; Wang Z
World J Surg Oncol; 2023 Aug; 21(1):258. PubMed ID: 37608278
[TBL] [Abstract] [Full Text] [Related]
10. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Behrouzi R; Armstrong AC; Howell SJ
Breast Cancer Res Treat; 2023 Nov; 202(1):83-95. PubMed ID: 37584881
[TBL] [Abstract] [Full Text] [Related]
11. Minimally Invasive Hepatopancreatobiliary Surgery at a Large Regional Health System: Assessing the Safety of Program Expansion.
Falls SJ; Maxwell CM; Kaye DJ; Dighe SG; Schiffman SC; Bartlett DL; Wagner PL; Allen CJ
Am Surg; 2024 Jan; 90(1):85-91. PubMed ID: 37578387
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant intensity modulated radiotherapy for a single and small (≤5 cm) hepatitis B virus-related hepatocellular carcinoma predicted to have high risks of microvascular invasion: a randomized clinical trial.
Wei X; Jiang Y; Feng S; Lu C; Huo L; Zhou B; Meng Y; Lau WY; Zheng Y; Cheng S
Int J Surg; 2023 Oct; 109(10):3052-3060. PubMed ID: 37352528
[TBL] [Abstract] [Full Text] [Related]
14. DNA methylation-based classifier differentiates intrahepatic pancreato-biliary tumours.
Dragomir MP; Calina TG; Perez E; Schallenberg S; Chen M; Albrecht T; Koch I; Wolkenstein P; Goeppert B; Roessler S; Calin GA; Sers C; Horst D; Roßner F; Capper D
EBioMedicine; 2023 Jul; 93():104657. PubMed ID: 37348162
[TBL] [Abstract] [Full Text] [Related]
15. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
de Mestier L; Resche-Rigon M; Dromain C; Lamarca A; La Salvia A; de Baker L; Fehrenbach U; Pusceddu S; Colao A; Borbath I; de Haas R; Rinzivillo M; Zerbi A; Funicelli L; de Herder WW; Selberherr A; Wagner AD; Manoharan P; De Cima A; Lybaert W; Jann H; Prinzi N; Faggiano A; Annet L; Walenkamp A; Panzuto F; Pedicini V; Pitoni MG; Siebenhuener A; Mayerhoefer ME; Ruszniewski P; Vullierme MP
J Neuroendocrinol; 2023 Jun; 35(6):e13311. PubMed ID: 37345276
[TBL] [Abstract] [Full Text] [Related]
16. Impact of aortoceliac angle in implantation of subcutaneous hepatic artery port-catheter system for hepatic arterial infusion chemotherapy via femoral approach.
Kim SH; Chun HJ; Kim Y; Oh JS; Choi BG; Lee HG
Acta Radiol; 2023 Sep; 64(9):2667-2672. PubMed ID: 37337646
[TBL] [Abstract] [Full Text] [Related]
17. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
Liang YH; Chen KH; Shao YY
Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
[TBL] [Abstract] [Full Text] [Related]
18. A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.
Xu K; Gao J; Feng L; Fang Y; Tang X
Front Immunol; 2023; 14():1203876. PubMed ID: 37292208
[TBL] [Abstract] [Full Text] [Related]
19. Risk Factors and Outcomes of Open Conversion During Minimally Invasive Major Hepatectomies: An International Multicenter Study on 3880 Procedures Comparing the Laparoscopic and Robotic Approaches.
Montalti R; Giglio MC; Wu AGR; Cipriani F; D'Silva M; Suhool A; Nghia PP; Kato Y; Lim C; Herman P; Coelho FF; Schmelzle M; Pratschke J; Aghayan DL; Liu Q; Marino MV; Belli A; Chiow AKH; Sucandy I; Ivanecz A; Di Benedetto F; Choi SH; Lee JH; Park JO; Prieto M; Guzman Y; Fondevila C; Efanov M; Rotellar F; Choi GH; Robles-Campos R; Wang X; Sutcliffe RP; Tang CN; Chong CC; D'Hondt M; Dalla Valle B; Ruzzenente A; Kingham TP; Scatton O; Liu R; Mejia A; Mishima K; Wakabayashi G; Lopez-Ben S; Pascual F; Cherqui D; Forchino F; Ferrero A; Ettorre GM; Levi Sandri GB; Sugioka A; Edwin B; Cheung TT; Long TCD; Abu Hilal M; Aldrighetti L; Fuks D; Han HS; Troisi RI; Goh BKP;
Ann Surg Oncol; 2023 Aug; 30(8):4783-4796. PubMed ID: 37202573
[TBL] [Abstract] [Full Text] [Related]
20. Impact of liver volumetric regeneration on survival outcomes in patients with hepatocellular carcinoma after major hepatectomy.
Nam NH; Yoh T; Hori Y; Morino K; Nishino H; Nishio T; Koyama Y; Ogiso S; Nagai K; Fukumitsu K; Uchida Y; Ito T; Ishii T; Seo S; Hata K; Taura K; Hatano E
Langenbecks Arch Surg; 2023 May; 408(1):193. PubMed ID: 37178235
[TBL] [Abstract] [Full Text] [Related]
[Next]
